Lamotrigine can be beneficial in patients with Dravet syndrome
Open accessAbstract
Dravet syndrome, a severe infantile epilepsy syndrome, is typically resistant to anti‐epileptic drugs (AED). Lamotrigine (LTG), an AED that is effective for both focal and generalized seizures, has been reported to aggravate seizures in Dravet syndrome. Therefore, LTG is usually avoided in Dravet syndrome. We describe two adults and a child with Dravet syndrome in whom LTG resulted in decreased seizure duration and frequency. This benefit was highlighted in each patient when LTG was withdrawn after 6 to 15 years, and resulted in an increased frequency of convulsive seizures together with longer seizure duration. A 25‐year‐old male required hospital admission for frequent seizures for the first time in 7 years, 6 weeks after ceasing LTG. Reintroduction of LTG improved seizure control, suggesting that in some patients with Dravet syndrome, LTG may be beneficial.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The SCB topiramate can be useful in Dravet syndrome, whereas others, such as lamotrigine and phenytoin, may exacerbate seizures in some patients and be helpful in others.
“However, the SCB topiramate can be useful in Dravet syndrome 181 , whereas others, such as lamotrigine and phenytoin, may exacerbate seizures in some patients and be helpful in others 208,209 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [208]
The Abstract reports that lamotrigine has been associated with seizure exacerbation but reduced seizures in the three patients described. It lists phenytoin among drugs that worsen seizures; it does not say phenytoin can help some patients. The topiramate statement has a separate citation and is not assessed here. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Epileptic Syndromes in Infancy, Childhood and Adolescence
Rogers, J., Bureau, M., Dravet, C., Dreifuss, F. E., Perret, A. P., Wolf, P., & Armstrong, D. L. (1993) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199307000-00012 · Cited by 1,465 · see citing works
The spectrum of SCN1A-related infantile epileptic encephalopathies
Harkin, L. A., McMahon, J. M., Iona, X., Dibbens, L. M., Pelekanos, J. T., Zuberi, S. M., Sadleir, L. G., Andermann, E., Gill, D. S., Farrell, K., et al. (2007) · Brain · doi:10.1093/brain/awm002 · Cited by 530 · see citing works
Self-citationLamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy
Guerrini, R., Dravet, C., Genton, P., Belmonte, A., Kaminska, A., & Dulac†, O. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01413.x · Cited by 467 · see citing works
Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients
Depienne, C., Trouillard, O., Saint‐Martin, C., Gourfinkel‐An, I., Bouteiller, D., Carpentier, W., Keren, B., Abert, B., Gautier, A., Baulac, S., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.062323 · Cited by 363 · see citing works
Genotype–phenotype associations in SCN1A -related epilepsies
Zuberi, S. M., Brunklaus, A., Birch, R. C., Reavey, E., Duncan, J., & FORBES, G. (2011) · Neurology · doi:10.1212/wnl.0b013e31820c309b · Cited by 252 · see citing works
Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology
Catarino, C. B., Liu, J. Y. W., Liagkouras, I., Gibbons, V. S., Labrum, R. W., Ellis, R., Woodward, C., Davis, M. B., Smith, S. J., Cross, J. H., et al. (2011) · Brain · doi:10.1093/brain/awr129 · Cited by 227 · see citing works
Self-citationExploring HCN channels as novel drug targets
Postea, O., & Biel, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3576 · Cited by 222 · see citing works
Successful use of fenfluramine as an add‐on treatment for Dravet syndrome
Ceulemans, B., Boel, M., Leyssens, K., Van Rossem, C., Neels, P., Jorens, P. G., & Lagae, L. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03495.x · Cited by 210 · see citing works
Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy
Nabbout, R., Chémaly, N., Chipaux, M., Barcia, G., Bouis, C., Dubouch, C., Leunen, D., Jambaqué, I., Dulac, O., Dellatolas, G., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-176 · Cited by 196 · see citing works
A long‐term follow‐up study of Dravet syndrome up to adulthood
Akiyama, M., Kobayashi, K., Yoshinaga, H., & Ohtsuka, Y. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02466.x · Cited by 192 · see citing works
Dravet syndrome (severe myoclonic epilepsy in infancy)
Dravet, C., & Oguni, H. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52891-9.00065-8 · Cited by 179 · see citing works
Severe myoclonic epilepsy of infancy (Dravet syndrome): Recognition and diagnosis in adults
Jansen, F. E., Sadleir, L. G., Harkin, L. A., Vadlamudi, L., McMahon, J. M., Mulley, J. C., Scheffer, I. E., & Berkovic, S. F. (2006) · Neurology · doi:10.1212/01.wnl.0000249312.73155.7d · Cited by 157 · see citing works
Self-citationThe pharmacologic treatment of Dravet syndrome
Chiron, C., & Dulac, O. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03007.x · Cited by 151 · see citing works
Chemical properties of antiepileptic drugs (AEDs)
Bialer, M. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.006 · Cited by 139 · see citing works
When is a child with status epilepticus likely to have Dravet syndrome?
Gal, F. L., Lebon, S., Ramelli, G. P., et al. (2014) · Epilepsy Research · doi:10.1016/j.eplepsyres.2014.02.019 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Zuberi, S. M., Wirrell, E., Yozawitz, E., Wilmshurst, J. M., Specchio, N., Riney, K., Pressler, R., Auvin, S., Samia, P., Hirsch, E., et al. (2022) · Epilepsia · doi:10.1111/epi.17239 · Cited by 934 · see citing works
Self-citationFavero, M., Sotuyo, N. P., Lopez, E., Kearney, J. A., & Goldberg, E. M. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.0193-18.2018 · Cited by 163 · see citing works
Developmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 128 · see citing works
Self-citationDoes long‐term phenytoin have a place in Dravet syndrome?
Zographos, G. A., Russ‐Hall, S. J., & Scheffer, I. E. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51684 · Cited by 17 · see citing works
Self-citation
- Authors
- Dalic, L., Mullen, S. A., Roulet Perez, E., & Scheffer, I.
- Affiliations
- Austin Health (AU)
- The University of Melbourne (AU)
- Paediatric Neurology and Neurorehabilitation Unit Centre Hospitalier Universitaire Vaudois Lausanne Switzerland
- Royal Children's Hospital (AU)
- Corresponding author
- Scheffer, Ingrid
- Venue
- Developmental Medicine & Child Neurology
- Publisher
- Wiley
- Published
- 2014-09-22
- Volume
- 57
- Issue
- 2
- Pages
- 200-202
- ISSN
- 0012-1622 (ISSN-L)
- 1469-8749
- OpenAlex
- W2083980682
- Cited by
- 64
- References
- 15
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 7 · 2020: 4 · 2019: 8 · 2018: 9 · 2017: 5 · 2016: 3 · 2015: 2 · 2014: 1
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Developmental Medicine & Child Neurology (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- State Government of Victoria
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Physiology › Diet and metabolism studies
- Keywords
- Dravet syndrome, lamotrigine, drug-resistant epilepsy, seizure control, seizure aggravation, antiepileptic drugs, convulsions, infantile epilepsy
- MeSH terms
- Lamotrigine, Adolescent, Adult, Anticonvulsants, Epilepsies, Myoclonic, Humans, Male, Seizures, Triazines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
